Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19
D. Bae, David M. Tehrani, Soniya V. Rabadia, Marlene H. Frost, Rushi V. Parikh, Marcella Calfon-Press, Olcay Aksoy, Soban Umar, Reza Ardehali, Amir B. Rabbani, Pooya Bokhoor, Ali Nsair, Jesse W. Currier, Jonathan M. Tobis, Gregg C. Fonarow, Ravi Dave, Asim Rafique
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Angiotensin receptorAngiotensin-converting enzymeAngiotensin-converting enzyme 2MedicineAngiotensin Receptor BlockersSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pharmacology2019-20 coronavirus outbreakRenin–angiotensin systemInternal medicineAngiotensin IIReceptorVirologyBlood pressureOutbreakInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19COVID-19 and Mental Health